Reprogramming the anti-tumor immune response via CRISPR genetic and epigenetic editing

Eric Alves,1,2 Shahama Taifour,1,2 Riccardo Dolcetti,3,4 Jonathan Chee,5,6 Anna K. Nowak,5,7 Silvana Gaudieri,1,8,9 and Pilar Blancafort1,2,10

Preclinical clustered regularly interspaced short palindromic repeats (CRISPR)-mediated genetic and epigenetic manipulation of the immune response has become a promising immunotherapeutic approach toward combating tumorigenesis and tumor progression. CRISPR-based immunologic reprogramming in cancer therapy comprises the locus-specific enhancement of host immunity, the improvement of tumor immunogenicity, and the suppression of tumor immunoevasion. To date, the ex vivo re-engineering of immune cells directed to inhibit the expression of immune checkpoints or to express synthetic immune receptors (chimeric antigen receptor therapy) has shown success in some settings, such as in the treatment of melanoma, lymphoma, liver, and lung cancer. However, advancements in nuclease-deactivated CRISPR-associated nuclease-9 (dCas9)-mediated transcriptional activation or repression and Cas13-directed gene suppression present novel avenues for the development of tumor immunotherapies. In this review, the basis for development, mechanism of action, and outcomes from recently published Cas9-based clinical trial (genetic editing) and dCas9/Cas13-based pre-clinical (epigenetic editing) data are discussed. Lastly, we review cancer immunotherapy-specific considerations and barriers surrounding use of these approaches in the clinic.

The human immune response consists of a complex and diverse array of molecular and cellular processes to differentiate between self and non-self, which allows it to defend and protect the host from pathogen infection, cellular damage, or neoplastic transformation. In the context of cancer, the constant selective pressure exerted by the host immune response often results in the selection of tumor variants capable of immune evasion that enable tumor cells to survive. Broadly, these tumor evasion mechanisms can involve (1) the accumulation of suppressive cells, such as CD4+ CD25+ FoxP3+ regulatory T cells (Tregs), in the cellular microenvironment;12 (2) down-modulation of the antigen processing and presentation pathways within the cancer cell;13,14 (3) shedding of stress, damage, or transformation markers at the cancer cell surface, including the six UL16 binding proteins (ULBP1–ULBP6) and major histocompatibility complex (MHC) class I polypeptide-related sequence A (MICA) and B (MICB);6–8 (4) secretion of immunosuppressive cytokines, particularly transforming growth factor β (TGF-β), vascular endothelial growth factor (VEGF), and interleukin-10 (IL-10), into the surrounding microenvironment;6,12 and (5) upregulation of immune checkpoint ligands, especially those pertaining to the programmed cell death-1 (PD-1) and cytotoxic T lymphocyte antigen-4 (CTLA-4) pathways.13–17 Although the last few decades have brought an improved understanding of the underlying molecular mechanisms of these immune evasion strategies, the development of safe and broadly effective immunotherapies that overcome these barriers and are applicable to multiple cancer types remains a formidable task. Accordingly, considerable research focus has been directed toward harnessing the high specificity of clustered regularly interspaced short palindromic repeats (CRISPR)-mediated genetic and epigenetic editing as emerging precision therapeutics to counter the aforementioned immune evasion mechanisms and improve anti-tumor immunity.

Numerous reviews to date have explored CRISPR-mediated genetic and epigenetic editing, yet comprehensive overviews of clinical and pre-clinical CRISPR technologies in cancer immunotherapy, particularly in the emerging epigenetic editing space, remain scarce. In this review, a brief outline of the mechanisms underlying the CRISPR-Cas9 (CRISPR-associated protein 9), dCas9 (nuclease deactivated Cas9) and Cas13 processes is presented, which encompasses the most advanced and clinically relevant DNA and RNA-targeting CRISPR systems developed thus far.18 This is then followed by an update on clinical Cas9-based and pre-clinical dCas9- and Cas13-mediated anti-tumor immunotherapies.

https://doi.org/10.1016/j.omtm.2021.04.009.

Correspondence: Pilar Blancafort, PhD, Cancer Epigenetics Laboratory, The Harry Perkins Institute of Medical Research, 6 Verdun Street, Nedlands, WA 6009, Australia.
E-mail: pilar.blancafort@uwa.edu.au
The efficiency of genome editing in this way varies greatly and is dependent on several factors, including the nature of the target and delivery method used. Notably, Mussolino et al. reviewed the editing efficiencies achieved in the case of the hematopoietic system and found that ex vivo editing is often 10%–30% efficient, whereas in vivo editing varies between 1% and 16%. However, with an optimized delivery system specific for the target cells, the Cas9 editing efficiency can increase up to 80%.26,37

### The CRISPR-dCas9 system

Beyond the success of the CRISPR-Cas9 system, the creation of the nuclease-deactivated Cas9 (dCas9) variant has widened the scope of CRISPR technologies into the field of epigenome engineering. The CRISPR-dCas9 system differs from the wild-type by two mutations (D10A and H840A), which inactivate Cas9’s cleavage capacity, while maintaining its RNA-guided DNA-binding specificity. As initially shown with engineered zinc finger proteins, dCas9 can be fused with various effector domains to mediate precise and programmable transcriptional activation or repression, editing of epigenetic marks, and fluorescent tagging of endogenous genes, all without directly editing the genome (Figure 1B).27–32

Locus-specific transcriptional manipulation in a guide-dependent manner was first achieved by fusing the VP64 (four copies of VP16, a herpes simplex virus transcription factor) recruiter of transcriptional activators, as well as Krüppel-associated box (KRAB) recruiter of transcriptional repressors, to dCas9. Since then, more complex arrays of mechanistically distinct effector domains have been described, which greatly improve the capability of dCas9 to induce transcriptional changes. This includes the VPR (tandem fusion of VP64, p65, and Rta domains) to generate the hybrid tripartite activator) in the case of gene activation, and the tandem fusion of KRAB with the TRD domain of MeCP2 to produce the dCas9-KRAB-MeCP2 repressor.27

As the arrays of effectors directly fused to dCas9 increase the size of the resulting protein, which in turn impact the expression of dCas9 and the intracellular delivery, alternative assembly methods have been developed. Notably, aptameric motifs engineered in combination with the gRNA scaffold (such as two copies of an RNA hairpin from the MS2 bacteriophage) were first described in the context of gene activation with the synergistic activation mediator (SAM) system. This approach has been exploited to combine multiple activator domains derived from epigenomic enzymes, such as the catalytic domain of DNA demethylases (e.g., TET1–2) or histone acetyltransferases (e.g., p300), to generate high levels of gene activation. Alternatively, repetitive peptide arrays that amplify and recruit specific designer antibody-fusion proteins can be fused to dCas9, as shown in the supernova tagging (SunTag) system. The dCas9-SunTag is based on single-chain variable fragment antibodies and the corresponding epitope, which offers major advantages, including high affinity and recognition of short peptide sequences. This system has previously been adapted to recruit DNA methyltransferases, including DNMT3A and DNMT3L, in order to induce locus-specific repression via DNA methylation, with minimal off-target binding. Importantly, these next-generation dCas9 systems (SAM and SunTag) provide highly specific, effective, and tunable tools for targeted epigenetic manipulation. Lastly, the further development of these technologies to enable simultaneous expression of multiple gRNAs (multiplexed transcriptional manipulation of distinct genes) continues to widen the scope and translatability of dCas9-based epigenetic editing.

In the arena of oncology, these dCas-based tools have demonstrated significant activation of tumor suppressor genes, such as PTEN (in breast cancer and melanoma), MASPIN (in breast and lung cancers), REPRIMO (in breast and gastric cancers), SARI (in colon cancer), and DKK3 (in prostate cancer). Similarly,  

---

**Table 1. Variation in protospacer-adjacent motif sequences across major Cas9 orthologs**

| CRISPR nuclease | Length (aa) | Organism | PAM sequence | Reference |
|-----------------|------------|----------|--------------|-----------|
| FrCas9 | 1,629 | Francisella novicida | NGG | 22 |
| TdCas9 | 1,423 | Treponema denticola | NAAAAN | 32 |
| SpCas9 | 1,368 | Streptococcus pyogenes | NGG, NAG | 21,23–25 |
| St1Cas9 | 1,122 | Streptococcus thermophiles 1 | NNARAAW | 23,26–28 |
| NmCas9 | 1,109 | Neisseria meningitides | NNNNGATT | 31,32 |
| SaCas9 | 1,053 | Staphylococcus aureus | NNGRN | |
| GjCas9 | 984 | Campylobacter jejuni | NNNVRYM | 33,34 |

4N = A/C/T/G; W = A/T; R = A/G; V = A/G/C; Y = T/C; M = A/C.
dCas9-mediated oncogene suppression has been achieved successfully in colon cancer (BRAF, HER2, and MYC), pancreatic cancer (KRAS), and liver cancer (GRN). In addition, several works outline that epigenome editing can be highly efficient, having achieved nearly complete gene repression or robust (several fold) gene activation, with minimal off-target effects, which mainly depend on the nature of effector domains used. For the most studied domains, such as VP64 and KRAB, off targets have been shown to be either zero or have negligible effects on non-cognate gene transcription. Finally, whereas Cas9 genome engineering unavoidably results in permanent changes, epigenetic approaches are reversible, circumventing the risk of inducing sequence changes in the target DNA, a key factor in the targeting of tumors harboring high degrees of genetic instability. Moreover, the durability of the epigenetic and
transcriptional changes induced by dCas9 editing can vary depending on the specific combination of effectors and may be dependent on the targeted loci. Thus, current research in the field of epigenome engineering faces the challenge to adapt the technology for the manipulation of different loci in diverse cell types with differing chromatin microenvironments.76

The CRISPR-Cas13 system

Beyond Cas9’s cleavage capability, Zhang and colleagues84–86 have pioneered the potential of catalytically inactive Cas13 (dCas13) in several applications. In particular, dCas13 has been fused with fluorescent tags to precisely label RNA molecules and assess RNA-specific Cas proteins. To date, the most successful of these technologies are those exploiting Cas13, of which four subtypes have been identified thus far: Cas13a (formerly known as C2c2), Cas13b, Cas13c, and Cas13d.80 In prokaryotes, Cas13 functions as an RNA-guided RNA endonuclease and operates as a defensive mechanism specific for viral RNAs.81 Unlike Cas9, the Cas13 effector family contains two higher eukaryotes and prokaryotes nucleotide-binding (HEPN) domains as its catalytic effectors, which confer RNase activity (Figure 1C). In addition, the Cas13 protein can form a complex with multiple crRNAs to cleave at multiple locations along an RNA transcript with high specificity and offers an alternative gene knockdown method to RNAi technologies (Figure 1D).82,83 Beyond Cas13’s cleavage capability, Zhang and colleagues84–86 have pioneered the potential of catalytically inactive Cas13 (dCas13) in several applications. In particular, dCas13 has been fused with fluorescent tags to precisely label RNA molecules and assess RNA-specific intracellular localization. Similarly, the fusion of dCas13 with deaminase domains from adenosine deaminases specific for RNA (ADARs) has been shown to mediate precise RNA editing to alter full-length transcripts containing pathogenic mutations. Individually and in combination, Cas9, dCas9, and Cas13 have shown great promise as therapeutic options for multiple diseases, such as cancer,70,87,88 viral infection,82,85,90 non-viral infection,91,92 and autoimmunity.93,94 In oncology, the ability of CRISPR-Cas to efficiently and specifically knock out (Cas9) or repress (dCas9 and Cas13) pro-tumorigenic genes or transcripts opens new strategies for tumor suppression.95–97 Moreover, the same system can be used to introduce (Cas9) or activate (dCas9) important immune-related genes to directly improve the host immune response.95,96 Consequently, the capacity of CRISPR-based systems to work individually as therapeutics and in combination with current immunotherapy strategies is developing into an emerging area of interest.

THE CRISPR-CAS9 SYSTEM DEMONSTRATES SAFETY IN ADOPTIVE T CELL IMMUNOTHERAPY

As of March 1, 2020, there have been 21 registered trials utilizing CRISPR-Cas systems aiming to genetically alter human T cells—a key adaptive immune cell type that responds specifically to antigens and is critical in host immunity (Table 2). These trials constitute approximately 48% (21/43) of all trials using CRISPR on the ClinicalTrials.gov registry. Recently, results from the first three CRISPR-Cas9 clinical trials were published by Jing et al.98 (Clinical-Trials.gov: NCT03081715), Lu et al.99 (Clinical-Trials.gov: NCT02793856), and Stadtmauer et al.100 (ClinicalTrials.gov: NCT03399448). Outcomes from these trials are discussed below.

PD-1 Knockout T cells

Many tumors, including esophageal squamous cell carcinoma (ESCC) and non-small cell lung cancer (NSCLC), express immune checkpoint PD-1 ligands (PD-L1s) that bind to PD-1 receptors on host T cells to inhibit their proliferation and cytokine production, thereby enabling immunoevasion (Figure 2).101–103 To date, anti-PD-1 and anti-PD-L1 monoclonal antibodies have shown success in many cancers, including melanoma,104 Hodgkin’s lymphoma,105 liver cancer,106 and lung cancer.107 However, given the potential of PD-1/PD-L1 inhibitor therapy to result in severe toxicity,108,109 genetic disruption of PD-1 expression on host T cells is seen as an alternative and potentially safer immunotherapeutic avenue. Jing et al.98 and Lu et al.99 independently investigated the safety of PD-1 knockout T cell reinfusion in 17 patients with advanced ESCC and 12 patients with metastatic NSCLC, respectively. In both trials, adoptive cell transfer (ACT) was used, whereby peripheral blood mononuclear cells (PBMCs) were collected, followed by ex vivo CRISPR-Cas9-mediated PD-1 (PDCD1 gene) knockout. The edited PBMCs were then selected, expanded, and reinfused back into each patient. In both studies, the regimen was well tolerated, with no serious (grade 3/4) treatment-related adverse events observed. No complete or partial responses were witnessed in either trial; however, approximately 35% (6/17) of ESCC patients and 18% (2/11; early withdrawal by one patient due to bacterial infection) of NSCLC patients exhibited stable disease. Results by Lu et al.99 demonstrated that co-transfection of Cas9 and sgRNA plasmid DNA (pDNA) via electroporation resulted in a low median editing efficiency of 5.81% (range, 0.42%–24.85%) in the 12 enrolled patients. In the edited PBMC pool, a median of 99.1% of cells were CD3 positive (range, 95.9%–99.6%), with CD3+CD8+ T cells accounting for 73.5% (range, 38.5%–93.0%). Whole-genome sequencing at 100-fold coverage targeted toward 2,086 sites determined by Cas-OFFinder110 detected no true off-target events, which constitute arguably the greatest cause for concern in CRISPR-Cas9 clinical applications. Ultimately, both trials appear to confirm that only minor (grade 1/2) adverse events, including fatigue, fever, joint pain, and skin rash, were attributed to the treatment, suggesting that CRISPR-Cas9-mediated ACT may be safe for clinical use. Moreover, although therapeutic efficacy was not the focus of these trials, they nonetheless highlight that significant improvements, such as a substantially increased editing efficiency, greater expansion of tumor-reactive T cells, enhanced antigen specificity, and a clearer understanding of the specific T cell subtypes undergoing the editing process, are required in order for an improved patient response. Importantly, both trials support that CRISPR-Cas9-based immunotherapy warrants further clinical investigation.
Multiplex PD-1 and TCR knockout

Results from the first phase I clinical trial to test the safety of multiplex CRISPR-Cas9 in treating patients with refractory cancer (ClinicalTrials.gov: NCT03399448) were published in February 2020 by Stadtmauer et al.100 Three patients were recruited and CRISPR-Cas9 was applied ex vivo to simultaneously disrupt expression of the PDCD1 gene (PD-1) and the endogenous T cell receptor α/β chain genes (TRAC, TRBC), which encode the T cell surface receptor (TCR) responsible for recognition of antigenic peptides presented in the context of MHC class I and II molecules. Patient CD3+ T cells were further transduced with TCRs specific for tumor antigen (NY-ESO-1) recognition to enhance anti-tumor responses. The same ACT process as above was used, with the engineered T cells being reinfused back into each patient following editing and expansion. Stable disease was seen in two patients, whereas the third patient exhibited disease progression. Importantly, no serious (grade 3/4) adverse events were caused by the treatment, with the re-infusion process and persistence of transduced cells being well tolerated by all patients. Unlike the plasmid-based delivery method used by Lu et al., 99 Stadtmauer et al.100 utilized electroporation of ribonucleoprotein (RNP) complexes composed of recombinant Cas9 loaded with equimolar mixtures of the three sgRNAs targeting each gene. In this case, the editing efficiency was approximately 20% for PDCD1, 45% for TRAC, and 15% for TRBC. Although RNP delivery shows significant improvements compared to plasmid-based systems,99 incomplete editing of TRAC/TRBC genes has previously been reported to result in mispairing and/or competing for expression between the transgenic TCR and endogenous TCR.111 Additionally, iGUIDE,112 a variant of GUIDE-seq (genome-wide unbiased identification of DSBs enabled by sequencing),113 determined three significant off-targets.

Table 2. Summary of all clinical trials utilizing CRISPR-Cas technologies to target the anti-tumor immune response

| Trial status | Identifier, ClinicalTrials.gov: | Phase | Country | Condition | Target gene | Edited cells |
|--------------|---------------------------------|-------|---------|-----------|-------------|--------------|
| Completed    | NCT03681715                     | 1     | China   | esophageal cancer | PD-1        | T cells     |
|              | NCT02793856                     | 1     | China   | lung cancer     | PD-1        | T cells     |
|              | NCT03044743                     | 1, 2  | China   | EBV-associated cancers | PD-1        | T cells     |
|              | NCT03166878                     | 1, 2  | China   | leukemia/lymphoma | TCR, B2M    | T cells     |
|              | NCT03398967                     | 1, 2  | China   | leukemia/lymphoma | CD19 and CD20 or CD22 | T cells |
|              | NCT03545815                     | 1     | China   | solid tumors    | TCR, PD-1   | T cells     |
|              | NCT04635434                     | 1     | United States, Australia, Germany | leukemia/lymphoma | CD19 | T cells     |
|              | NCT04037566                     | 1     | China   | leukemia/lymphoma | HPK1        | T cells     |
|              | NCT04244656                     | 1     | United States, Australia, Canada, Spain | multiple myeloma | BCMA | T cells     |
|              | NCT04417764                     | 1     | China   | liver cancer    | PD-1        | T cells     |
|              | NCT04246669                     | 1, 2  | United States | gastrointestinal cancer | CISH | T cells     |
|              | NCT04438083                     | 1     | United States, Australia | kidney cancer | CD70 | T cells     |
|              | NCT04502446                     | 1     | United States, Australia | lymphoma | CD70 | T cells     |
|              | NCT04557436                     | 1     | United Kingdom | leukemia | CD19, CD52, TCR | T cells |
|              | NCT04637763                     | 1     | United States | lymphoma | CD19 | T cells     |
| Terminated   | NCT03690011                     | 1     | United States | leukemia/lymphoma | CD7, CD28 | T cells     |
| Withdrawn    | NCT03399448                     | 1     | United States | multiple myeloma | TCR, PD-1 | T cells     |
|              | NCT02863913                     | 1     | China   | bladder cancer  | PD-1        | T cells     |
|              | NCT02867332                     | 1     | China   | kidney cancer   | PD-1        | T cells     |
|              | NCT02867345                     | 1     | China   | prostate cancer | PD-1        | T cells     |
| Unknown1     | NCT03747965                     | 1     | China   | solid tumors    | PD-1        | T cells     |

Terms used in search: CRISPR, clustered regularly interspaced short palindromic repeat. PD-1, programmed cell death-1; EBV, Epstein-Barr virus; CISH, cytokine-induced SH2 protein; TCR, T cell receptor; HPK1, hematopoietic progenitor kinase 1; CD, cluster of differentiation; B2M, β2-microglobulin; BCMA, B cell maturation antigen. Search cutoff date: March 1, 2020.

1Unknown studies denote those whose last known status was recruiting, not yet recruiting, or active, but had passed the completion date, and the status had not been last verified within the past 2 years.
The first, caused by the TRAC sgRNA, affected the transcriptional unit of chloride intracellular channel 2 (CLIC2) and was deemed acceptable, as it is not reported to be expressed in T cells. The remaining two off-targets, within the genes encoding zinc finger protein 609 (ZFN609) and long intergenic non-protein coding RNA 377 (LINC00377), were attributed to the TRBC sgRNA. Both off-targets were also deemed by the authors as acceptable due to their minimal impact on the gene (ZFN609) and unknown role to date (LINC00377). Despite the small sample size, Stadtmauer et al. sup-
served as an alternative to monoclonal antibody treatment that targets immune checkpoint inhibitors (ICIs), such as PD-1 or CTLA-4, which have been effective in only a subset of cancers. Aside from the suitable safety documented in the above CRISPR-Cas9-based anti-tumor immunotherapy clinical trials, the small sample sizes and high variability in survival of individual patients limit definitive conclusions on the efficacy of these treatments. However, with a number of current CRISPR-based trials targeted toward boosting the immune response via manipulation of immune-related genes (Table 2), more conclusive results are likely to be seen during the coming months.

**EPIGENETIC EDITING BY CRISPR-dCas9 CAN IMPROVE ANTI-TUMOR HOST IMMUNITY**

While major modalities of cancer immunotherapy, such as ICIs and ACT, have revolutionized cancer treatment, not all patients respond to these therapies. Often, durable immune responses occur in patients with immunogenic ("hot") tumors, characterized by infiltrating CD4+ and CD8+ T cells and accumulation of pro-inflammatory mediators. However, non-immunogenic ("cold") tumors that lack these components have significantly reduced response rates, although some patients still respond, and cold tumors may require conversion into a more hot-like phenotype in order to achieve a better outcome. The CRISPR-dCas9-mediated epigenetic modulation of tumor immunogenicity represents one such conversion method. In this approach, dCas9-mediated transcriptional activation of pro-immunogenic genes, or repression of genes involved in tumor immunoevasion and immunosuppression, may enhance tumor immunogenicity. Studies using these methods have shown success in pre-clinical testing and hold great potential for novel immunotherapeu-
tics, as discussed below.
Pro-immunogenic transcriptional activation
In a seminal 2019 publication by Wang et al., a multiplexed dCas9-SAM system was harnessed to induce a genome-scale simultaneous upregulation of endogenous pro-immunogenic genes in triple-negative breast cancer (TNBC) E0771 cells, in order to improve tumor immunogenicity. Given their role as inducers of T cell proliferation and activation, a particular focus was directed toward the upregulation of CD70, CD80, CD86, IFNα4, IFNβ1, and IFNγ genes. CD70, present on antigen-presenting cells (APCs; dendritic cells, B cells, and macrophages) and some T cells, is the cognate ligand for the tumor necrosis factor (TNF) receptor family member CD27 on T cells, and it provides an essential co-stimulatory signal for T cell activation. Similarly present on APCs and some T cells, CD80 and CD86 are cognate ligands for the co-stimulatory receptor CD28 on T cells and also play a critical role in T cell activation. Type I (α and β) and type II (γ) interferons (IFNs) are potent cytokines that bind to the ubiquitously expressed IFNα receptor (IFNαR) and IFNγR, respectively. Most cell types can produce IFNβ, whereas IFNα is predominantly produced by plasmacytoid dendritic cells and IFNγ is chiefly secreted by activated T cells and natural killer (NK) cells. Together, type I and II IFN signaling promotes innate and adaptive immunity in a variety of ways, including activation of antigen presentation and chemokine production, enhanced antibody generation, and stimulation of T cell and NK cell cytotoxicity. The transcriptional upregulation mediated by dCas9-SAM resulted in amplified presentation of a model antigen (ovalbumin) in vitro. Moreover, the edited E0771 cells transplanted into syngeneic immunocompetent (C57BL/6j) mice demonstrated significantly reduced tumor volume in vivo compared to both immunodeficient (nude and Rag-deficient) mice and CD4+ and CD8+ T cell-depleted immunocompetent mice. Additionally, Wang et al. combined their activation system with anti-CTLA4 monoclonal antibodies, which substantially increased the efficacy of anti-CTLA4 therapy, with complete tumor regression of established tumors. As expected, the increased tumor immunogenicity via dCas9-mediated transcriptional activation of pro-immunogenic genes increased CD4+ and CD8+ T cell infiltration into the tumor, thereby improving anti-tumor immunity. The findings were also supported by Liu et al.’s earlier work from 2017, where HeLa cells edited using the same dCas9-SAM system to overexpress the IFNγ gene exhibited enhanced apoptosis, inhibited proliferation, and overall reduced tumor volume when implanted in immunodeficient (severe combined immunodeficiency (SCID)) mice. Collectively, both works provide a proof of concept that manipulating the transcriptome of tumors in favor of a pro-immunogenic phenotype can greatly improve the anti-tumor immune response and the response to ICIs. Moreover, the activation of endogenous cytokines, such as IFNγ, within the tumor is likely to be an excellent starting point for this novel approach of enhancing tumor immunogenicity.

Immunosuppressive pathway inhibition
The TGF-β signaling axis has been of interest owing to its dual role in both tumor suppression and progression. When functioning as an oncogenic activator, TGF-β signaling induces an immunosuppressive response, which is further potentiated by reciprocal positive regulatory interactions with Notch and Hippo signaling. Recently, microRNA-524 (miR-524) has been shown to silence the TGF-β, Notch, and Hippo pro-tumorigenic signaling pathways simultaneously by suppression of SMAD2, HES1, and TEAD1 genes, respectively, making it an attractive target for cancer immunotherapy. As such, in 2019, Liu et al. aimed to explore the potential of dCas9-VP64-mediated miRNA-524 transcriptional activation as a cancer immunotherapy strategy to inhibit TGF-β/Notch/Hippo signaling in vivo. To this end, a pH-responsive multistage delivery nanoparticle (MDNP) was developed to deliver pDNA encoding the CRISPR-dCas9 system and sgRNA biomolecular components targeting the miR-524 locus. The systemic injection of MDNP/dCas9-miR-524 into tumor-bearing immunodeficient (nude) mice with TNBC MDA-MD-231 xenograft evidenced reduced SMAD2, HES1, and TEAD1 gene and protein expression, significantly inhibiting tumor growth and higher levels of tumor apoptosis. Although the direct impact of miR-524 activation on tumor immunogenicity was not explored in this study, inhibition of the TGF-β axis is well recognized to improve immune cell infiltration as a consequence of the reduction in immunosuppression, tumor migration, and angiogenesis. Altogether, Liu et al.’s work provides a strong rationale for further exploration of miR-524 in cancer immunotherapy and highlights the potential of CRISPR-dCas9 technologies to inhibit immunosuppressive pathways for an improved anti-tumor response.

Although not applied in pre-clinical studies, a number of early works also suggest that dCas9-based methods can help circumvent other major tumor immunoevasion mechanisms. For instance, impairment of Treg immunosuppressive function by dCas9-KRAB-mediated forkhead box P3 (FoxP3) transcriptional repression, dCas9-SAM-mediated enhancement of neoplastic transformation markers, such as MICA, and dCas9-KRAB-directed repression of immunosuppressive cytokine receptors have demonstrated that dCas9-mediated epigenetic engineering has potential in multiple facets of cancer immunotherapy. Ultimately, dCas9-mediated epigenetic editing to improve tumor immunogenicity and/or boost the host’s anti-tumor immune response opens new therapeutic avenues, particularly in combination with ICI or ACT therapies (Figure 2).

THE CRISPR-CAS13 SYSTEM IS A NOVEL GENE INTERFERENCE TOOL IN CANCER IMMUNOTHERAPY
Significant attention has been directed toward applying CRISPR-Cas13 (RNA-targeting) technology as a diagnostic in the detection of low-frequency cancer somatic mutations and in RNA editing. Additionally, the CRISPR-Cas13 system has demonstrated highly efficient and specific knockdown of oncogenic mutant drivers, gene fusions, and ncRNA transcripts in vitro with minimal off-targets, highlighting its potential for use as a RNA-based therapeutic tool. More recently, the potential of Cas13-based gene suppression in cancer immunotherapy has drawn attention due to its growing success in pre-clinical studies, as explored below.
PD-L1 disruption
As discussed above, CRISPR-mediated PD-1 knockout T cells have shown acceptable toxicity profiles, yet their efficacy remains limited. Moreover, although PD-1 knockout therapies largely focus on T cells, other important immune effectors, such as NK cells, are also inhibited by the PD-1/PD-L1 axis. Therefore, as opposed to targeting PD-1 expression on specific cell types, Zhang et al. explored the capability of CRISPR-Cas13a to silence PD-L1 expression at the tumor cell surface to improve overall anti-tumor immunity. To this end, pDNA encoding Cas13a and crRNAs targeting PD-L1 transcripts were systemically delivered in vivo using a pH and hydrogen peroxide (H₂O₂)-responsive dual-locking nanoparticle (DLNP). Following injection of DLNP/Cas13-crRNA into melanoma B16F10-bearing immunocompetent mice, significant tumor growth suppression and improved survival was observed. Furthermore, a significant reduction in TGF-β and elevation in IFNγ, TNF-α (predominantly secreted by macrophages and promotes T cell activation), IL-2 (secreted by activated T cells and promotes T cell proliferation), and IL-12 (secreted by activated APCs to activate NK cells and induce T cell differentiation) levels were seen in treated tumors, suggesting activation of anti-tumor immunity. Knockdown of PD-L1 by Cas13 also increased the number of CD8+ tumor-infiltrating T cells, reduced the number of myeloid-derived suppressor cells (MDSCs), and induced a tumor-associated macrophage polarization from a tumor-promoting M2-like (CD206hiCD11b+F4/80+) to a more anti-tumor M1-like (CD80hiCD11b+F4/80+) phenotype in the tumor microenvironment. This work suggests that Cas13a can successfully suppress tumor PD-L1 expression and aid in eliciting an effective anti-tumor immune response (Figure 2).

VEGF pathway disruption
The VEGF/VEGFR receptor pathway constitutes one of the most promising therapeutic targets due to its significant immunosuppressive role in the tumor and surrounding microenvironment. Previously, obstruction of VEGF receptor 2 (VEGFR2) and its downstream signaling pathways, BCL-2 and Survivin, via small-molecule inhibitors or neutralizing antibodies has shown success in blocking tumor growth and prolonging survival. However, limitations, such as temporary efficacy, treatment resistance, and adverse complications, have justifiably limited their clinical use. With this in mind, Fan et al. explored the capacity of the Cas13a system to target VEGFR2, BCL-2, and Survivin transcripts simultaneously in tumor cells. Plasmid DNA containing Cas13a and crRNA tandem sequences designed to target VEGFR2/BCL-2/Survivin transcripts were encapsulated in a dual-component liposome system coated in VEGFR2 monocolonal antibodies. The Cas13a/liposome was then perfused via intravesical administration into bladder cancer 5637 cell-bearing immunodeficient (nude) mice, resulting in significantly reduced transcription levels of VEGFR2/BCL-2/Survivin and inhibited tumor growth. It is well established that inhibition of the VEGF/VEGFR axis reduces angiogenesis and Treg/MDSC accumulation, thereby promoting immune cell infiltration into the tumor. These findings therefore support that Cas13a represents an emerging precision medicine platform for the inhibition of tumor growth by targeting pro-oncogenic signaling pathways, such as VEGF/VEGFR, in a highly selective manner.

More recent studies have shown that dCas13-fusion (RNA editing) proteins can also achieve efficient knockdown of endogenous RNA transcripts by catalyzing the demethylation of m6A (N6-methyladenosine), or by the degradation of m6A-marked RNA, resulting in gene suppression. These early works suggest that dCas13-based technologies targeted toward m6A modifications may offer an alternative to Cas13-mediated alteration of post-transcriptional RNA fate. Although more investigation is required to explore the efficacy and safety of Cas13 in cancer immunotherapy, studies support that Cas13 has the potential to function as a therapeutic through its targeted manipulation of tumor immunogenicity (Figure 2).

CONSIDERATIONS FOR CRISPR-BASED CANCER IMMUNOTHERAPY
To date, many reviews have discussed the key considerations surrounding use of CRISPR in treating human diseases. For further details on the concerns surrounding use of CRISPR-based therapeutics in a general sense, we refer to excellent previously published reviews. In this section, however, we focus specifically on the concerns associated with CRISPR use in cancer immunotherapy.

Pre-existing CRISPR immunity
Given that CRISPR systems are derived from common human pathogens, such as Streptococcus pyogenes and Staphylococcus aureus, the presence of pre-existing immunity from prior exposure remains a major concern in the safety and efficacy of these technologies. Principally, in the context of cancer immunotherapy where potent immune activation is the goal, the extent of anti-Cas antibodies and/or T cells that may interfere with CRISPR-based treatment needs to be elucidated. Recently, three studies have shown that both antibodies and T cells against Streptococcus pyogenes Cas9 (SpCas9) and Staphylococcus aureus Cas9 (SaCas9) are indeed present in many individuals, supporting that further investigation is required. First, Simhadri et al. highlighted that approximately 2.5% and 10% of donors (a predominantly white cohort from the United States) tested positive for anti-SpCas9 and anti-SaCas9 antibodies in human sera, respectively, by enzyme-linked immunosorbent assay (ELISA). Second, Wagner et al. identified using flow cytometry that approximately 96% of donors (ethnicity unknown) had SpCas9-reactive peripheral CD4+ and CD8+ T cells as measured by CD137 expression. Lastly, Charlesworth et al. identified using PBMCs that approximately 58% and 78% of donors (a predominantly white cohort from the United States) had antibodies against SpCas9 and SaCas9 detected using ELISA, respectively. Moreover, approximately 67% and 78% of donors were positive for SpCas9- and SaCas9-reactive CD4+/CD8+ T cells, respectively, as confirmed by IFNγ enzyme-linked immunosorbent assay (ELISPot), intracellular cytokine staining (ICS), and/or surface expression of CD137 or CD154. Although these studies complement one another in highlighting the prevalence of pre-existing immunity to Cas9, further research is still required to elucidate whether the presence of anti-Cas antibodies or anti-Cas T cells are at biologically
MDNP136 and DLNP 149 methods discussed in the pre-clinical successful delivery systems designed with this is mind include the immune interactions until cargo release may be required. Examples of the likelihood of producing anti-Cas9 memory T cells during the use is vital. In these cases, preclinical assessment of Cas immunogenicity and selecting for tissue-specific delivery methods that do not allow for CRISPR-immune interactions until cargo release may be required. Examples of successful delivery systems designed with this is mind include the MDNP136 and DLNP149 methods discussed in the pre-clinical dCas9 and Cas13 sections, respectively. These delivery systems are also necessary to ensure that the CRISPR cargo is delivered directly to the target tissue. For instance, the release of CRISPR-dCas9 with sgRNAs targeting pro-immunogenic genes in unintended tissues may elicit an adverse pro-inflammatory and/or autoimmune response. Ultimately, averting an anti-CRISPR immune response will likely require a joint approach of checking for pre-existing immunity and selecting for tissue-specific, multi-layered, non-immunogenic delivery systems.

**Retroactivity in multiplex CRISPR applications**

One of the key benefits of CRISPR-based systems is their capability to multiplex crRNAs and, thus, to regulate multiple targets simultaneously. For cancer immunotherapy, it is highly likely that clinical benefit will only be achieved through multiplexing, as multiple genetic elements require editing. However, as the number of target sites increases, there is also a subsequent increase in the competition between crRNAs to guide the Cas protein to their target site. Competition between crRNAs, termed retroactivity, results in a decrease in the performance of CRISPR-Cas and severely hinders the ability to predict crRNA targeting efficiency. This presents a major obstacle in cancer immunotherapy, as it is essential that maximum gene editing and transcriptional regulation is achieved. In other contexts, retroactivity has been mitigated by using conditional crRNAs, whose activity is dependent on the presence or absence of an RNA trigger. However, this is unlikely to serve in cancer immunotherapy, as simultaneous targeting is required. An alternative method more applicable to overcoming retroactivity in cancer immunotherapy lies in the exploitation of target hierarchy. In this approach, targets of high priority are allocated multiple crRNAs, while lower priority targets are allocated only a single crRNA. This method may ensure that all sites are targeted, but those of high importance are emphasized. Furthermore, it is still unclear as to how many crRNAs can be expressed in vivo for an effective multiplexing strategy, while maintaining editing efficacy at all target sites. This knowledge is fundamental to achieving the desired effectiveness of CRISPR-based therapies. In the case of cancer immunotherapy, it is expected that not all target sites will have the same impact on tumor immunogenicity or immune effector cytotoxicity. Also, inherent genetic and/or epigenetic differences between patients at specific target sites is highly likely. Therefore, effective multiplexed strategies that target these different loci is essential.

Altogether, if pre-existing CRISPR immunity and retroactivity can be mitigated via improved delivery systems and crRNA prioritization/customization to particular patients, then CRISPR-based cancer immunotherapy may yet develop to become an effective clinical treatment.

**CONCLUDING REMARKS AND FUTURE PERSPECTIVES**

The ability of CRISPR-based technologies to efficiently modify specific loci at the genetic and epigenetic level provides novel opportunities to reprogram the immune response for improved tumor elimination. To date, CRISPR-Cas9 genetic editing has successfully improved the killing capacity of T cells via the elimination and/or modification of key cell surface molecules, such as PD-1 and the TCR. However, although shown to be safe when used ex vivo, Cas9’s potential to bind to non-target DNA sequences (off-targets), thereby causing permanent genomic instability or disruption of otherwise normal host genes, has consistently remained a major concern. Alternatively, the development of dCas9- and Cas13-based systems that work transiently, are reversible, and eliminate the risk of long-lasting consequences are expected to be safer, and therefore more clinically relevant, for in vivo use. Technologies such as dCas9 in particular show significant advantages, as it mediates straightforward upregulation or downregulation of transcription and editing of epigenetic marks within the same platform, which significantly expand its applications in cancer therapeutics. Moreover, these systems are increasingly being developed as inducible structures allowing for precise control of epigenetic editing at will. Still, safe and precise delivery mechanisms are yet to be addressed in a comprehensive way, and the potential for adverse immune reactions challenges clinical CRISPR applications. Altogether, based on safety and versatility, epigenetic editing platforms such as dCas9 and Cas13 are likely to overtake Cas9 genetic editing platforms in clinical applications.

Future applications of CRISPR-based technologies in the immunotherapy field are likely to expand heavily on epigenetic editing by dCas9 or Cas13. Epigenetically reprogramming immune evasion mechanisms, such as rescuing MHC class I/II expression, halting MICA/B shedding, and repressing the activation of suppressive cytokines, is an attractive therapeutic avenue, as doing so has the potential to greatly improve host immunity. Furthermore, the expanding knowledge of the role of distinct immune checkpoint inhibitors will offer grounds for the identification of additional checkpoint molecules.
to be edited in multiplexed CRISPR applications. Selective epigenetic targeting of immune checkpoints in effector immune cells or at the tumor cell surface to improve \textit{in vivo} immune activation and efficacy is likely to improve patient outcomes in the clinic. Other potential applications may involve the epigenetic manipulation of cells used in ACT aiming at enhancing intra-tumoral recruitment and persistence of these cells through the upregulation of relevant chemokine receptors, such as CXCR2 and CXCR3, which greatly improve T cell localization and migration to tumors.\textsuperscript{171} In principle, this strategy could be combined with epigenetic upregulation of the genes encoding for the corresponding chemokine ligands on tumor cells, thus facilitating the treatment of cold-like tumors, which are poorly amenable by current immunotherapies. Similarly, recent studies have highlighted the complexity in the development of exhausted T cells and NK cells (failure to produce cytokines, lack of proliferation, and high expression of inhibitory receptors),\textsuperscript{174–177} with significant epigenetic changes identified in chronically stimulated NK cells\textsuperscript{178} and T cells that failed to respond to anti-PD-1 therapy.\textsuperscript{179,180} Reinvigoration of exhausted and dysfunctional cell subsets using targeted epigenetic CRISPR editing of key genes, such as TCF1 (transcription factor encoded by TCF7 crucial for T cell persistence and NK cell survival),\textsuperscript{181–183} may assist in improving patient responses to ICI therapies and overall anti-tumor immunity. Importantly, the extent to which CRISPR-based technologies can alter the tumor landscape is still unknown; however, through multiplexed approaches, it is hopeful that durable immune responses can be achieved. Although in its infancy, precise epigenetic editing by dCas9 and Cas13 is likely to become a powerful tool in both basic scientific research and clinical application, especially when combined with Cas9-mediated genetic editing.

ACKNOWLEDGMENTS
We thank Dr. Emily Golden (The Harry Perkins Institute of Medical Research) for assistance with the figures. This work was supported by the National Health and Medical Research Council (NHMRC) (APP1187328, APP1109428, APP1165208, APP1147528, APP1130212, and APP1197652); the National Institutes of Health (R01CA170370 and R01DA036906); the National Breast Cancer Foundation (IIRS-18-47 and IIRS-20-124); the Cancer Council (CA190006); Cure Brain Cancer (NBCNBCF19-009); and by US DOD Peer Reviewed Cancer Research Program (CA190006). P.B. is a recipient of an Australian Research Council Future Fellowship (FT130101767), a Cancer Council of Western Australia Research Fellowship, and a Wesfarmers Women’s Cancers Fellowship. J.C. is a recipient of a WA Department of Health Merit Award; E.A. is a recipient of an Australian Government Research Training Program Scholarship at The University of Western Australia, a BioZone PhD Scholarship at The University of Western Australia, and a Cancer Council WA PhD Top Up Scholarship. Funding for the open access charge was provided by the National Health and Medical Research Council (NHMRC).

AUTHOR CONTRIBUTIONS
Conceptualization, E.A., P.B., and S.G.; writing – original draft, E.A., S.T., R.D., and J.C.; writing – review & editing, E.A., P.B., R.D., J.C., S.G., and A.K.N.; figures, E.A.; funding acquisition, P.B.; supervision, P.B., and S.G.

DECLARATION OF INTERESTS
The authors declare no competing interests.

REFERENCES
1. Curiel, T.J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J.R., Zhang, L., Burrow, M., et al. (2004). Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10, 942–949.
2. Saito, T., Nishikawa, H., Wada, H., Nagano, Y., Sugiyama, D., Atarashi, K., Maeda, Y., Hamaguchi, M., Ohkura, N., Sato, E., et al. (2016). Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers. Nat. Med. 22, 679–684.
3. Koopman, L.A., Corver, W.E., van der Slak, A.R., Giphart, M.J., and Fleuren, G.J. (2000). Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer. J. Exp. Med. 191, 961–976.
4. Siddle, H.V., Kreiss, A., Tovar, C., Yuon, C.K., Cheng, Y., Below, K., Swift, K., Pearse, A.-M., Hamede, R., Jones, M.E., et al. (2013). Reversible epigenetic down-regulation of MHC molecules by devil facial tumour disease illustrates immune escape by a contagious cancer. Proc. Natl. Acad. Sci. USA 110, 5103–5108.
5. Burr, M.L., Sparber, C.E., Chan, K.L., Chan, Y.-C., Kersberg, A., Lam, E.Y.N., Arais-Yates, E., Vassiladiadis, D., Bell, C.C., Gilan, O., et al. (2019). An evolutionarily conserved function of polycomb silences the MHC class I antigen presentation pathway and enables immune evasion in cancer. Cancer Cell 36, 385–401.e8.
6. Ashiru, O., Boutet, P., Fernández-Messina, L., Agüera-González, S., Skepper, J.N., Valés-Gómez, M., and Reyburn, H. (2010). Natural killer cell cytotoxicity is suppressed by exposure to the human NKG2D ligand MICA*008 that is shed by tumor cells in exosomes. Cancer Res. 70, 481–489.
7. Chitadze, G., Lettau, M., Bhat, J., Wesch, D., Steinle, A., Fürst, D., Mytilineou, J., Kalkhoff, H., Janssen, O., Oberh, H.-H., and Kabelitz, D. (2013). Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: heterogeneous involvement of the “a disintegrin and metalloproteases” 10 and 17. Int. J. Cancer 133, 1557–1566.
8. Ferrari de Andrade, L., Kumar, S., Luoma, A.M., Ito, Y., Alves da Silva, P.H., Pan, D., Pyndol, J.W., Yoon, C.H., and Wucherpfennig, K.W. (2020). Inhibition of MICA and MICB shedding elicits NK-cell-mediated immunity against tumors resistant to cytotoxic T cells. Cancer Immunol. Res. 8, 769–780.
9. Donkor, M.K., Sarkar, A., Savage, P.A., Franklin, R.A., Johnson, L.K., Jungbluth, A.A., Allison, J.P., and Li, M.O. (2011). T cell surveillance of oncogene-induced prostate cancer is impeded by T cell-derived TGF-β1 cytokine. Immunity 35, 123–134.
10. Courau, T., Nehar-Belaid, D., Florer, L., Levacher, B., Vazquez, T., Brimaud, F., Bellier, B., and Klitzmann, D. (2016). TGF-β and VEGF cooperatively control the immunotolerant tumor environment and the efficacy of cancer immunotherapies. JCI Insight 1, e85974.
11. Gavlas, N.G., Tsitas, M., Tsitsilonis, O., Politi, E., Ioannou, K., Ziosas, A.C., Rodolakis, A., Vlahos, G., Thomakos, N., Haidopoulos, D., et al. (2012). VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2. Br. J. Cancer 107, 1869–1875.
12. Vahl, J.M., Friedrich, J., Mitlter, S., Trump, S., Heim, L., Kacherl, K., Balabko, L., Fuhrlich, N., Geppert, C.-L., Trafa, D.L., et al. (2017). Interleukin-10 regulated tumour tolerance in non-small cell lung cancer. Br. J. Cancer 117, 1644–1655.
13. Parsa, A.T., Waldron, J.S., Pannier, A., Crane, C.A., Parney, I.F., Barry, J.J., Cachola, K.E., Murray, J.C., Tihan, T., Jensen, M.C., et al. (2007). Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat. Med. 13, 84–88.
14. Taube, J.M., Anders, R.A., Young, G.D., Xu, H., Sharma, R., McMiller, T.L., Chen, S., Klein, A.P., Pardoll, D.M., Topalian, S.L., and Chen, L. (2012). Colocalization of inflammatory response with B7-H1 expression in human melanocytic lesions.
supports an adaptive resistance mechanism of immune escape. Sci. Transl. Med. 4, 127ra37.

15. Gordon, S.R., Maute, R.L., Dufken, B.W., Hutter, G., George, B.M., McCracken, M.N., Gupta, R., Tsai, J.M., Sinha, R., Corey, D., et al. (2017). PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature 545, 495–499.

16. Leach, D.R., Krummel, M.F., and Allison, J.P. (1996). Enhancement of antitumor immunity by CTLA-4 blockade. Science 271, 1734–1736.

17. Peggs, K.S., Quezada, S.A., Chambers, C.A., Korman, A.J., and Allison, J.P. (2009). Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J. Exp. Med. 206, 1717–1725.

18. Pickar-Oliver, A., and Gersbach, C.A. (2019). The next generation of CRISPR-Cas technologies and applications. Nat. Rev. Mol. Cell Biol. 20, 490–507.

19. Barrangou, R., Fremaux, C., Deveau, H., Richards, M., Boyaval, P., Moineau, S., Romero, D.A., and Horvath, P. (2007). CRISPR provides acquired resistance against viruses in prokaryotes. Science 315, 1709–1712.

20. Brouns, S.J.J., Jore, M.M., Lundgren, M., Westra, E.R., Slijkhuis, R.H.J., Snijders, A.P.L., Dickman, M.J., Makarova, K.S., Koonin, E.V., and van der Oost, J. (2008). Small CRISPR RNAs guide antiviral defense in prokaryotes. Science 321, 960–964.

21. Jenne, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J.A., and Charpentier, E. (2012). A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816–821.

22. Hirano, H., Gootenberg, J.S., Horvath, P., and Moineau, S. (2008). Phage response to CRISPR-encoded resistance. Science 321, 1390–1400.

23. Beltran, A.S., Russo, A., Lara, H., Fan, C., Lizardi, P.M., and Blancafort, P. (2011). Reactivation of dormant tumor suppressor genes maspin by targeting protein transcription factors. Mol. Cancer Ther. 10, 7718–7727.

24. Beltran, A.S., Sun, X., Lizardi, P.M., and Blancafort, P. (2011). Reprogramming epigenetic silencing: artificial transcription factors synergize with chromatin remodeling drugs to reactivate the tumor suppressor mammary serum protease inhibitor. Mol. Cancer Ther. 10, 1080–1090.

25. Beltran, A.S., Russo, A., Lara, H., Fan, C., Lizardi, P.M., and Blancafort, P. (2011). Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell 152, 1173–1183.

26. Beltran, A., Parihi, S., Liu, Y., Cuevas, B.D., Johnson, G.L., Futschik, B.W., and Blancafort, P. (2007). Re-activation of a dormant tumor suppressor gene maspin by designed transcription factors. Oncogene 26, 2791–2798.

27. Beltran, A., Parihi, S., Liu, Y., Cuevas, B.D., Johnson, G.L., Futschik, B.W., and Blancafort, P. (2007). Re-activation of a dormant tumor suppressor gene maspin by designed transcription factors. Oncogene 26, 2791–2798.

28. Beltran, A., Beaton, L., and Blancafort, P. (2011). Reprogramming epigenetic silencing: artificial transcription factors synergize with chromatin remodeling drugs to reactivate the tumor suppressor mammary serum protease inhibitor. Mol. Cancer Ther. 10, 7718–7727.

29. Blackman, M.D., Kohli, S., Poon, M.T., Kasper, J., and Lander, E.S. (2012). Natural Human CTCs harbor CRISPR/Cas9 endonuclease activity. Cell 150, 1115–1126.

30. Blackman, M.D., Kohli, S., Poon, M.T., Kasper, J., and Lander, E.S. (2012). Natural Human CTCs harbor CRISPR/Cas9 endonuclease activity. Cell 150, 1115–1126.

31. Blackman, M.D., Kohli, S., Poon, M.T., Kasper, J., and Lander, E.S. (2012). Natural Human CTCs harbor CRISPR/Cas9 endonuclease activity. Cell 150, 1115–1126.

32. Blackman, M.D., Kohli, S., Poon, M.T., Kasper, J., and Lander, E.S. (2012). Natural Human CTCs harbor CRISPR/Cas9 endonuclease activity. Cell 150, 1115–1126.

33. Blackman, M.D., Kohli, S., Poon, M.T., Kasper, J., and Lander, E.S. (2012). Natural Human CTCs harbor CRISPR/Cas9 endonuclease activity. Cell 150, 1115–1126.

34. Blackman, M.D., Kohli, S., Poon, M.T., Kasper, J., and Lander, E.S. (2012). Natural Human CTCs harbor CRISPR/Cas9 endonuclease activity. Cell 150, 1115–1126.

35. Blackman, M.D., Kohli, S., Poon, M.T., Kasper, J., and Lander, E.S. (2012). Natural Human CTCs harbor CRISPR/Cas9 endonuclease activity. Cell 150, 1115–1126.

36. Blackman, M.D., Kohli, S., Poon, M.T., Kasper, J., and Lander, E.S. (2012). Natural Human CTCs harbor CRISPR/Cas9 endonuclease activity. Cell 150, 1115–1126.
genomic loci in living human cells by an optimized CRISPR/Cas system. Cell 155, 1479–1491.

53. Gilbert, L.A., Larson, M.H., Morsut, L., Liu, Z., Brar, G.A., Torres, S.E., Stern-Ginossar, N., Brandman, O., Whitehead, E.H., Doudna, J.A., et al. (2013). CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell 154, 442–451.

54. Perez-Pinera, P., Kocak, D.D., Vockley, C.M., Adler, A.F., Kabadi, A.M., Polstein, L.R., Thakore, P.I., Glass, K.A., Ousterout, D.G., Leong, K.W., et al. (2013). RNA-guided gene activation by CRISPR-Cas9-based transcription factors. Nat. Methods 10, 973–976.

55. Maeder, M.L., Linder, S.J., Cascio, V.M., Fa, Y., Ho, Q.H., and Joung, J.K. (2013). Epigenome editing by a CRISPR-Cas9-based modular RNA-targeting CRISPR effector. Nucleic Acids Res. 41, 506–517.

56. Chen, A., Schulte, J., Zhao, Y., Song, Z., Liu, D., Hsu, D., Zhang, F., Prins, P.R., and Doudna, J.A. (2016). Multiplexed genome engineering by Cas12a and CRISPR arrays encoded on single RNA molecules. Science 353, 272–276.

57. Chang, F. and Hsu, D.P. (2016). CRISPR-Cas tools for transcriptional repression and activation. Nat. Methods 13, 800–803.

58. Chang, J.S., Banerjee, A., Ma, L., Wang, H., and Arkin, A.P. (2016). CRISPR-Cas9 epigenetic regulation of preclinical precision medicine. Nucleic Acids Res. 44, 572–581.

59. Chen, J., Wang, J., Yang, W., Li, W., Li, Y., and Guo, X. (2016). CRISPR-Cas9-based epigenome editing by a single-component programmable RNA-guided RNA-targeting CRISPR effector. Science 353, 588–591.

60. Chen, J., Wang, J., Yang, W., Li, W., Li, Y., and Guo, X. (2016). CRISPR-Cas9-based epigenome editing by a single-component programmable RNA-guided RNA-targeting CRISPR effector. Science 353, 588–591.

61. Cheng, H., Wang, J., Yang, W., Li, W., Li, Y., and Guo, X. (2016). CRISPR-Cas9-based epigenome editing by a single-component programmable RNA-guided RNA-targeting CRISPR effector. Science 353, 588–591.

62. Chong, H., Zhang, F., and Doudna, J.A. (2016). CRISPR-Cas9 epigenetic regulation of preclinical precision medicine. Nucleic Acids Res. 44, 572–581.

63. Chong, H., Zhang, F., and Doudna, J.A. (2016). CRISPR-Cas9 epigenetic regulation of preclinical precision medicine. Nucleic Acids Res. 44, 572–581.

64. Chong, H., Zhang, F., and Doudna, J.A. (2016). CRISPR-Cas9 epigenetic regulation of preclinical precision medicine. Nucleic Acids Res. 44, 572–581.

65. Chong, H., Zhang, F., and Doudna, J.A. (2016). CRISPR-Cas9 epigenetic regulation of preclinical precision medicine. Nucleic Acids Res. 44, 572–581.

66. Chong, H., Zhang, F., and Doudna, J.A. (2016). CRISPR-Cas9 epigenetic regulation of preclinical precision medicine. Nucleic Acids Res. 44, 572–581.

67. Chong, H., Zhang, F., and Doudna, J.A. (2016). CRISPR-Cas9 epigenetic regulation of preclinical precision medicine. Nucleic Acids Res. 44, 572–581.

68. Chong, H., Zhang, F., and Doudna, J.A. (2016). CRISPR-Cas9 epigenetic regulation of preclinical precision medicine. Nucleic Acids Res. 44, 572–581.

69. Chong, H., Zhang, F., and Doudna, J.A. (2016). CRISPR-Cas9 epigenetic regulation of preclinical precision medicine. Nucleic Acids Res. 44, 572–581.

70. Chong, H., Zhang, F., and Doudna, J.A. (2016). CRISPR-Cas9 epigenetic regulation of preclinical precision medicine. Nucleic Acids Res. 44, 572–581.
determinants of Plasmodium falciparum invasion. Proc. Natl. Acad. Sci. USA 114, E9356–E9365.

92. Xiao, B., Yin, S., Hu, Y., Sun, M., Wei, J., Huang, Z., Wen, Y., Dai, X., Chen, H., Mu, J., et al. (2019). Epigenetic editing by CRISPR/dCas9 in Plasmodium falciparum. Proc. Natl. Acad. Sci. USA 116, 255–260.

93. Wu, J., Yang, S., Yu, D., Gao, W., Liu, X., Zhang, K., Fu, X., Bao, W., Zhang, K., Yu, J., et al. (2019). CRISPR/cas9 mediated knockout of an intergenic variant rs6927172 identified IL-20RA as a new risk gene for multiple autoimmune diseases. Genes Immun. 20, 103–111.

94. Giménez, C.A., Ielpi, M., Mutto, A., Grosembacher, L., Arygbay, P., and Pereya-Bonnet, F. (2016). CRISPR-on system for the activation of the endogenous human INS gene. Gene Ther. 23, 543–547.

95. Sánchez-Rivera, F.J., and Jackson, T. (2015). Applications of the CRISPR-Cas9 system in cancer biology. Nat. Rev. Cancer 15, 387–395.

96. Ansari, I., Chaturvedi, A., Chikara, D., and Singh, S. (2021). CRISPR/Cas mediated epigenome editing for cancer therapy. Semin. Cancer Biol. , Published online January 6, 2021. https://doi.org/10.1016/j.semcancer.2020.12.018.

97. Granados-Riveron, J.T., and Aquino-Jarquin, G. (2018). CRISPR-Cas13 precision transcriptome engineering in cancer. Cancer Res. 78, 4107–4113.

98. Jing, Z., Zhang, N., Ding, L., Wang, X., Hua, Y., Jiang, M., and Wu, S.X. (2018). Safety and activity of programmed cell death-1 gene knockout engineered t cells in patients with previously treated advanced esophageal squamous cell carcinoma: An open-label, single-arm phase I study. J. Clin. Oncol. 36 (15, Suppl.), 3054. https://doi.org/10.1200/JCO.2018.36.15_suppl.3054.

99. Lu, Y., Xue, J., Deng, T., Zhou, X., Yu, K., Deng, L., Huang, M., Yi, X., Liang, M., Lu, Y., Xue, J., Deng, T., Zhou, X., Yu, K., Deng, L., Huang, M., Yi, X., Liang, M., et al. (2020). Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small cell lung cancer. Nat. Med. 26, 732–740.

100. Stadtmueller, E.A., Fratetta, J.T., Davis, M.M., Cohen, A.D., Weber, K.L., Lancaster, E., Mungar, P.A., Kulikovskaya, I., Gupta, M., Chen, F., et al. (2020). CRISPR-engineered T cells in patients with refractory cancer. Science 367, eaba7365.

101. Ishida, Y., Agata, Y., Shibahara, K., and Honjo, T. (1992). Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 11, 3887–3895.

102. Iwai, Y., Terawaki, S., and Honjo, T. (2005). PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Cancer Res. 65, 543–547.

103. Schadenhof, D., Hodi, F.S., Robert, C., Weber, J.S., Margolin, K., Hamid, O., Fitch, B., Chen, T.T., Bernan, D.M., and Wolchok, J.D. (2015). Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J. Clin. Oncol. 33, 1889–1894.

104. Naidoo, J., Wang, J., Woo, K.M., Jyrhov, T., Halpenny, D., Cunningham, J., Chaft, J.E., Segal, N.H., Callahan, M.K., Lesokhin, A.M., et al. (2017). Pneumonitis in patients treated with anti-programmed death-1 programmed death ligand 1 therapy. J. Clin. Oncol. 35, 709–717.

105. Bae, S., Park, J., and Kim, J.-S. (2014). Cas-OFFinder: A fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases. Bioinformatics 30, 1473–1475.

106. Schober, K., Müller, T.R., Göken, F., Grassmann, E., Eifenberger, M., Potorak, M., Stemberger, C., Schumann, K., Roth, T.L., Marson, A., and Busch, D.H. (2019). Orthotopic replacement of T-cell receptor α- and β-chains with preservation of near-physiological T-cell function. Nat. Biomed. Eng. 3, 974–984.

107. Nishino, M., Giobbie-Hurder, A., Hatabu, H., Ramaiya, N.H., and Hodi, F.S. (2016). Induction of programmed cell death-1 inhibitor–related pneumonitis in patients with advanced cancer: A systematic review and meta-analysis. JAMA Oncol. 2, 1607–1616.
interactions of T-cells with antigen-presenting dendritic cells and B-cells. PLoS ONE 7, e45185.

127. Menezes, S.M., Decanini, D., Brassat, D., Khouri, R., Schnittman, S.V., Kruschewsky, R., López, G., Alvarez, C., Talledo, M., Gotuzzo, E., et al. (2014). CD80- and CD86+ B cells as biomarkers and possible therapeutic targets in HTLV-1 associated myelopathy/ tropical spastic paraparesis and multiple sclerosis. J. Neuroinflammation 11, 18.

128. Propper, D.J., Chao, D., Braybrooke, J.P., Bahl, P., Thavasu, P., Balkwill, F., Turley, H., Dobbs, N., Gatter, K., Talbot, D.C., et al. (2003). Low-dose IFN-γ induces tumor MHC expression in metastatic malignant melanoma. Clin. Cancer Res. 9, 84–92.

129. Braun, D., Caramallo, I., and Demengot, J. (2002). IFN-γ enhances BCR-dependent B-cell responses. Int. Immunol. 14, 411–419.

130. Liu, S., Yu, X., Wang, Q., Liu, Z., Xiao, Q., Hou, P., Hu, Y., Hou, W., Yang, Z., Guo, D., and Chen, S. (2017). Specific expression of interferon-γ induced by synergetic activation mediator-derived systems activates innate immunity and inhibits tumor-gene expression. J. Microbiol. Biotechnol. 27, 1855–1866.

131. Siegel, P.M., Shu, W., Cardiff, R.D., Muller, W.J., and Massagué, J. (2003). Transforming growth factor-β signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proc. Natl. Acad. Sci. USA 100, 8430–8435.

132. Bruna, A., Darken, R.S., Rojo, F., Ocaña, A., Peñuelas, S., Arias, A., París, R., Tortosa, A., Mora, J., Basela, B., and Seoane, J. (2007). High TGF-β-Smad activity confers poor prognosis in glcoma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer Cell 11, 147–160.

133. Mariatham, S., Turley, S.J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel, Zhao, K., Wang, Q., Wang, Y., Huang, K., Yang, C., Li, Y., Yi, K., and Kang, C. (2018). Lin, D., Hiron, T.K., and O (2020). Innovative precision gene-editing tools in personalized cancer medicine. Adv. Sci. (Weinh.) 7, 1801423.

134. Dittrich, F., Mazocco, A., Fernandez, J., Peidró, F.J., Papapicco, P., Fabregat, I., De Santis, F., Paradiso, A., Sabbà, C., and Giannelli, G. (2013). Differential inhibition of the TGF-β axis modulates the natural killer cell versus multiple myeloma effect: A therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 116, 2286–2294.

135. Zhang, Z., Chen, J., Zhu, Z., Zhu, Z., Lao, X., Wu, J., Cheng, J., Zhang, X., Mei, H., and Yang, G. (2021). CRISPR-Cas13-mediated knockdown of lncRNA-GACAT3 inhibited cell proliferation and motility, and induced apoptosis by increasing p21, Bax, and e-cadherin expression in bladder cancer. Front. Mol. Biosci. 7, 627777.

136. Benson, D.M., Jr., Bukan, C.E., Mishra, A., Hofmeister, C.C., Efebera, Y., Becknell, B., Biaocchi, R.A., Zhang, J., Yu, J., Smith, M.K., et al. (2010). The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: A therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 116, 2286–2294.

137. Fan, J., Liu, Y., Liu, L., Huang, Y., Li, X., and Huang, W. (2020). A multifunction lipid-based CRISPR-Cas13a genetic circuit delivery system for bladder cancer gene therapy. ACS Synth. Biol. 9, 343–355.

138. Terme, M., Pernot, S., Marcheteau, E., Sandoval, F., Benhamouda, N., Colussi, O., Dubreuil, O., Carpenter, A.F., Tartour, E., and Taieb, J. (2013). VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. Cancer Res. 73, 539–549.

139. Huang, H., Langenkamp, E., Georganaki, M., Loskog, A., Fuchs, P.F., Dieterich, L.C., Kreuger, J., and Dimberg, A. (2015). VEGF suppresses T-lymphocyte infiltration in the tumor microenvironment through inhibition of NF-kB-induced endothelial activation. FASEB J. 29, 227–238.

140. Liu, P., Atkinson, S.J., Akhabrein, S.E., Zhou, Z., Munsterberg, A., Robinson, S.D., and Bao, Y. (2017). Sulforaphane exerts anti-angiogenesis effects against hepatocellular carcinoma through inhibition of STAT3/HIF-1α/VEGF signalling. Sci. Rep. 7, 12651.

141. Rauch, S., He, C., and Dickinson, B.C. (2018). Targeted mRNA demethylation using an engineered dCas9-ALKBH5 fusion protein. Nucleic Acids Res. 46, 5684–5694.

142. Rauch, S., He, C., and Dickinson, B.C. (2018). Targeted mRNA demethylation using an engineered dCas9-ALKBH5 fusion protein. Nucleic Acids Res. 46, 5684–5694.

143. Bao, Y. (2017). Sulforaphane exerts anti-angiogenesis effects against hepatocellular carcinoma through inhibition of STAT3/HIF-1α/VEGF signalling. Sci. Rep. 7, 12651.

144. Liu, P., Atkinson, S.J., Akhabrein, S.E., Zhou, Z., Munsterberg, A., Robinson, S.D., and Bao, Y. (2017). Sulforaphane exerts anti-angiogenesis effects against hepatocellular carcinoma through inhibition of STAT3/HIF-1α/VEGF signalling. Sci. Rep. 7, 12651.

145. You, L., Tong, R., Li, M., Liu, Y., Xue, J., and Lu, Y. (2019). Advancements and obstacles of CRISPR-Cas9 technology in translational research. Mol. Ther. Methods Clin. Dev. 13, 359–370.

146. Dai, X., Blancafort, P., Wang, P., Sgro, A., Thompson, E.W., and Ostroukhov, K.K. (2020). Innovative precision gene-editing tools in personalized cancer medicine. Adv. Sci. (Weinh.) 7, 1902552.
162. Li, A., Tanner, M.R., Lee, C.M., Hurley, A.E., De Giorgi, M., Jarrett, K.E., Davis, T.H., Doerfler, A.M., Bao, G., Beeton, C., and Lagor, W.R. (2020). AAV-CRISPR gene editing is negated by pre-existing immunity to Cas9. Mol. Ther. 28, 1432–1441.

163. Simhadri, V.L., McGill, J., McMahon, S., Wang, J., Jiang, H., and Sauna, Z.E. (2018). Prevalence of pre-existing antibodies to CRISPR-associated nuclease Cas9 in the USA population. Mol. Ther. Methods Clin. Dev. 10, 105–112.

164. Wagner, D.L., Amini, L., Wendering, D.J., Burkhardt, L.M., Akyiuz, L., Reinke, P., Volk, H.D., and Schmuck-Hennesse, M. (2019). High prevalence of Streptococcus pyogenes Cas9-reactive T cells within the adult human population. Nat. Med. 25, 242–248.

165. Charlesworth, C.T., Drehpande, P.S., Dever, D.P., Camarena, J., Lengart, Y.T., Cromer, M.K., Yakulikas, C.A., Gollingwood, M.A., Zhang, L., Bode, N.M., et al. (2019). Identification of preexisting adaptive immunity to Cas9 proteins in humans. Nat. Med. 25, 249–254.

166. Zhang, S., and Voigt, C.A. (2018). Engineered dCas9 with reduced toxicity in bacteria: implications for genetic circuit design. Nucleic Acids Res. 46, 11115–11125.

167. Hanewich-Hollatz, M.H., Chen, Z., Hochrein, L.M., Huang, J., and Pierce, N.A. (2019). Conditional guide RNAs: Programmable conditional regulation of CRISPR/Cas function in bacterial and mammalian cells via dynamic RNA nanotechnology. ACS Cent. Sci. 5, 1241–1249.

168. Fu, Y., Foden, J.A., Khayter, C., Maeder, M.L., Reyon, D., Joung, J.K., and Sander, D.R. (2013). High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat. Biotechnol. 31, 822–826.

169. Pattanayak, V., Lin, S., Guilinger, J.P., Ma, E., Doudna, J.A., and Liu, D.R. (2013). High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity. Nat. Biotechnol. 31, 839–843.

170. Gao, Y., Xiong, X., Wong, S., Charles, E.J., Lim, W.A., and Qi, L.S. (2016). Complex transcriptional modulation with orthogonal and inducible dCas9 regulators. Nat. Methods 13, 1043–1049.

171. Kershaw, M.H., Wang, G., Westwood, J.A., Pachynski, R.K., Tiffany, H.L., Marincola, F.M., Wang, E., Young, H.A., Murphy, P.M., and Hwu, P. (2002). Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with the transcription factor Tcf1. Hum. Gene Ther. 13, 1971–1980.

172. Peng, W., Ye, Y., Rabinovich, B.A., Liu, C., Lou, Y., Zhang, M., Whittington, M., Yang, Y., Overwijk, W.W., Lizée, G., and Hwu, P. (2010). Transduction of tumor-specific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses. Clin. Cancer Res. 16, 5458–5468.

173. Mikucki, M.E., Fisher, D.T., Matsuzaki, J., Skitzki, J.J., Gaulin, N.B., Muhitch, J.B., Ku, A.W., Frelinger, J.G., Odunsi, K., Gajewski, T.F., et al. (2015). Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints. Nat. Commun. 6, 7458.

174. Doering, T.A., Crawford, A., Angelosanto, J.M., Paley, M.A., Ziegler, C.G., and Wherry, E.J. (2012). Network analysis reveals centrally connected genes and pathways involved in CD8+ T cell exhaustion versus memory. Immunity 37, 1130–1144.

175. Fourcade, I., Sun, Z., Pagliano, O., Guillaume, P., Luescher, I.F., Sander, C., Kirkwood, J.M., Olive, D., Kuchroo, V., and Zarour, H.M. (2012). CD8+ T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res. 72, 887–896.

176. Gill, S., Vasey, A.E., De Souza, A., Baker, J., Smith, A.T., Kohrt, H.E., Florek, M., Gibbs, K.D., Jr., Tate, K., Ritchie, D.S., and Negrin, R.S. (2012). Rapid development of exhaustion and down-regulation of coexpressor in vivo the antitumor activity of adoptively transferred murine natural killer cells. Blood 119, 5758–5768.

177. Sun, C., Xu, J., Huang, Q., Huang, M., Wen, H., Zhang, C., Wang, J., Song, J., Zheng, M., Sun, H., et al. (2016). High NKG2A expression contributes to NK cell exhaustion and predicts a poor prognosis of patients with liver cancer. OncoImmunology 5, e126562.

178. Merino, A., Zhang, B., Dougherty, P., Luo, X., Wang, J., Blazar, B.R., Miller, J.S., and Cichocki, F. (2019). Chronic stimulation drives human NK cell dysfunction and epigenetic reprogramming. J. Clin. Invest. 129, 3770–3785.

179. Miller, B.C., Sen, D.R., Al Aboosy, R., Bi, K., Virkud, Y.V., LaFleur, M.W., Yates, K.R., Lakos, A., Felt, K., Naik, G.S., et al. (2019). Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. Nat. Immunol. 20, 326–336.

180. Pauken, K.E., Sammons, M.A., Odorizzi, P.M., Manne, S., Godec, J., Khan, O., Drake, A.M., Chen, Z., Sen, D.R., Kurachi, M., et al. (2016). Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. Science 354, 1160–1165.

181. Sade-Feldman, M., Yizhak, K., Bjorgaard, S.L., Ray, J.P., de Boer, C.G., Jenkins, R.W., Lieb, D.J., Chen, Z., Sen, D.R., Kurachi, M., et al. (2016). Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell 175, 998–1013.e20.

182. Siddiqui, I., Schaeuble, K., Chennupati, V., Fuertes Marraco, S.A., Calderon-Copete, S., Pas Ferreira, D., Carmona, S.I., Scarpellino, L., Géller, D., Pradervand, S., et al. (2019). Intratumoral Tcf1+PD-1+CD8+ T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy. Immunity 50, 215–221.e10.

183. Jeevan-Raj, B., Gehrig, J., Charnroy, M., Chennupati, V., Grandclément, C., Angelino, P., Delorenzi, M., and Held, W. (2017). The transcription factor Tcf1 contributes to normal NK cell development and function by limiting the expression of granzymes. Cell Rep. 20, 613–626.